NASDAQ:AUPH

Aurinia Pharmaceuticals News Headlines

$12.64
-0.16 (-1.25 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.46
Now: $12.64
$12.73
50-Day Range
$12.30
MA: $13.44
$15.95
52-Week Range
$12.01
Now: $12.64
$20.50
Volume1.19 million shs
Average Volume4.42 million shs
Market Capitalization$1.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.87

Headlines

Aurinia Pharmaceuticals (NASDAQ AUPH) News Headlines Today

SourceHeadline
Aurinia Pharmaceuticals (NASDAQ:AUPH) Earns "Buy" Rating from SVB LeerinkAurinia Pharmaceuticals (NASDAQ:AUPH) Earns "Buy" Rating from SVB Leerink
americanbankingnews.com - April 11 at 6:22 AM
Aurinias Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data ShowsAurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
finance.yahoo.com - April 8 at 12:31 PM
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical MeetingsAurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
finance.yahoo.com - April 8 at 7:30 AM
Aurinia Should Be A Long-Term Winner With Lupkynis Now On The MarketAurinia Should Be A Long-Term Winner With Lupkynis Now On The Market
seekingalpha.com - March 25 at 2:02 PM
AUPH Apr 2021 12.000 callAUPH Apr 2021 12.000 call
uk.finance.yahoo.com - March 22 at 7:01 PM
AUPH Apr 2021 15.000 putAUPH Apr 2021 15.000 put
uk.finance.yahoo.com - March 22 at 2:01 PM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Expected to Announce Quarterly Sales of $3.95 MillionAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Expected to Announce Quarterly Sales of $3.95 Million
americanbankingnews.com - March 22 at 1:48 AM
 Brokerages Expect Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Announce -$0.34 Earnings Per Share Brokerages Expect Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Announce -$0.34 Earnings Per Share
americanbankingnews.com - March 20 at 4:08 PM
First Week of May 21st Options Trading For Aurinia Pharmaceuticals (AUPH)First Week of May 21st Options Trading For Aurinia Pharmaceuticals (AUPH)
nasdaq.com - March 20 at 8:53 AM
3 Favorite Names With Exciting Potential3 Favorite Names With Exciting Potential
finance.yahoo.com - March 15 at 1:36 PM
Aurinia Pharmaceuticals: Short-Term Trading of a Long-Term FavoriteAurinia Pharmaceuticals: Short-Term Trading of a Long-Term Favorite
finance.yahoo.com - March 11 at 12:49 PM
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2020 Results - Earnings Call TranscriptAurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 26 at 3:31 PM
Aurinia Pharmaceuticals Inc. 2020 Q4 - Results - Earnings Call PresentationAurinia Pharmaceuticals Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 26 at 1:49 PM
Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call TranscriptAurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 1:18 AM
Earnings Preview: Aurinia PharmaceuticalsEarnings Preview: Aurinia Pharmaceuticals
benzinga.com - February 23 at 12:33 PM
Is a Surprise Coming for Aurinia (AUPH) This Earnings Season?Is a Surprise Coming for Aurinia (AUPH) This Earnings Season?
msn.com - February 23 at 12:33 PM
Vaxart (VXRT) to Report Q4 Earnings: Whats in the Cards?Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
markets.businessinsider.com - February 18 at 4:54 AM
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
finance.yahoo.com - February 17 at 7:27 AM
Canadian biotech to prioritize Rockville growth, ‘shift gears’ post-FDA approvalCanadian biotech to prioritize Rockville growth, ‘shift gears’ post-FDA approval
bizjournals.com - February 15 at 2:10 PM
Were Not Worried About Aurinia Pharmaceuticals (TSE:AUP) Cash BurnWe're Not Worried About Aurinia Pharmaceuticals' (TSE:AUP) Cash Burn
finance.yahoo.com - February 14 at 8:58 AM
Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14
seekingalpha.com - February 2 at 7:24 PM
Shark Bites: Anatomy of a Trade - Aurinia PharmaceuticalsShark Bites: Anatomy of a Trade - Aurinia Pharmaceuticals
finance.yahoo.com - February 1 at 1:02 PM
Heres Why Everybodys Talking About Aurinia Pharmaceuticals StockHere's Why Everybody's Talking About Aurinia Pharmaceuticals Stock
finance.yahoo.com - January 27 at 9:18 AM
Why Aurinia Pharma, AstraZeneca And More Are Trading Higher TodayWhy Aurinia Pharma, AstraZeneca And More Are Trading Higher Today
msn.com - January 25 at 12:57 PM
AUPH Jan 2022 3.000 callAUPH Jan 2022 3.000 call
ca.finance.yahoo.com - January 24 at 7:37 PM
FDA Approves Aurinia Pharmas Lupkynis - Second Lupus Nephritis Drug In A Month FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month
markets.businessinsider.com - January 23 at 5:12 AM
The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug ApplicationsThe Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications
markets.businessinsider.com - January 17 at 9:51 PM
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock OptionsImplied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
finance.yahoo.com - January 11 at 12:07 PM
Will Aurinia Pharmas Lupus Nephritis Drug Pass FDA Muster?Will Aurinia Pharma's Lupus Nephritis Drug Pass FDA Muster?
nasdaq.com - January 11 at 7:06 AM
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare ConferencesAurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
finance.yahoo.com - January 8 at 7:58 AM
AUPH Jan 2023 30.000 putAUPH Jan 2023 30.000 put
ca.finance.yahoo.com - January 5 at 11:44 PM
Aurinia (AUPH) Looks Good: Stock Adds 5.5% in SessionAurinia (AUPH) Looks Good: Stock Adds 5.5% in Session
finance.yahoo.com - December 28 at 9:22 AM
Aurinia Pharmaceuticals: An UpdateAurinia Pharmaceuticals: An Update
seekingalpha.com - December 21 at 2:45 PM
Aurinia Pharmaceuticals Offers Good Entry Opportunity Before Next PDUFA For VoclosporinAurinia Pharmaceuticals Offers Good Entry Opportunity Before Next PDUFA For Voclosporin
seekingalpha.com - December 21 at 9:45 AM
Aurinia Inks Voclosporin Deal With Otsuka For Europe, Japan; Analyst Sees 53% UpsideAurinia Inks Voclosporin Deal With Otsuka For Europe, Japan; Analyst Sees 53% Upside
nasdaq.com - December 20 at 1:29 PM
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply DealThe Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal
benzinga.com - December 16 at 8:04 AM
Heres What Aurinia Pharmaceuticals Inc.s (TSE:AUP) Shareholder Ownership Structure Looks LikeHere's What Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shareholder Ownership Structure Looks Like
finance.yahoo.com - December 15 at 9:51 AM
Aurinia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AUPHAurinia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AUPH
nasdaq.com - December 4 at 3:48 PM
February 2021 Options Now Available For Aurinia Pharmaceuticals (AUPH)February 2021 Options Now Available For Aurinia Pharmaceuticals (AUPH)
nasdaq.com - November 6 at 12:29 PM
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - November 5 at 3:21 PM
Aurinia Pharma’s Dry Eye Study Blanks on Late-Stage ResultsAurinia Pharma’s Dry Eye Study Blanks on Late-Stage Results
markets.businessinsider.com - November 4 at 12:00 AM
Why Aurinia Pharmaceuticals Stock Is Trading Lower TodayWhy Aurinia Pharmaceuticals Stock Is Trading Lower Today
benzinga.com - November 3 at 7:00 PM
Aurinia Pharmas Dry Eye Study Blanks on Late-Stage ResultsAurinia Pharma's Dry Eye Study Blanks on Late-Stage Results
msn.com - November 3 at 1:59 PM
Aurinia suspends voclosporin program as Phase 2/3 study fails to achieve significant improvement in dry eye syndromeAurinia suspends voclosporin program as Phase 2/3 study fails to achieve significant improvement in dry eye syndrome
seekingalpha.com - November 3 at 8:58 AM
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye SyndromeAurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
finance.yahoo.com - November 2 at 7:11 PM
AUPH Nov 2020 24.000 putAUPH Nov 2020 24.000 put
sg.finance.yahoo.com - October 30 at 10:45 PM
AUPH Nov 2020 18.000 putAUPH Nov 2020 18.000 put
sg.finance.yahoo.com - October 30 at 12:43 PM
AUPH Nov 2020 11.000 putAUPH Nov 2020 11.000 put
sg.finance.yahoo.com - October 30 at 7:43 AM
AUPH Nov 2020 22.000 putAUPH Nov 2020 22.000 put
ca.finance.yahoo.com - October 29 at 8:26 AM
AUPH Nov 2020 11.000 callAUPH Nov 2020 11.000 call
ca.finance.yahoo.com - October 29 at 8:26 AM
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.